Calmare Therapeutics Inc. (CTTC) financial statements (2021 and earlier)

Company profile

Business Address 1375 KINGS HIGHWAY EAST
FAIRFIELD, CT 06824
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0000000
Cash and cash equivalents0000000
Receivables0000000
Inventory, net of allowances, customer advances and progress billings 44  4 
Inventory 44  4 
Prepaid expense0000000
Other current assets 00  0 
Other undisclosed current assets4  4404
Total current assets:4444444
Noncurrent Assets
Property, plant and equipment0000000
Other undisclosed noncurrent assets0000000
Total noncurrent assets:0000000
TOTAL ASSETS:4444444
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8446445
Accounts payable2222222
Accrued liabilities3112202
Employee-related liabilities00 000 
Interest and dividends payable2222 11
Debt6554433
Derivative instruments and hedges, liabilities0000000
Deferred revenue and credits 00  0 
Other undisclosed current liabilities4774675
Total current liabilities:18171615151413
Noncurrent Liabilities
Long-term debt and lease obligation   0000
Long-term debt, excluding current maturities   0000
Total noncurrent liabilities:   0000
Total liabilities:18171615151413
Stockholders' equity
Stockholders' equity attributable to parent, including:(14)(13)(12)(11)(10)(10)(9)
Common stock0000000
Additional paid in capital49494949494948
Accumulated deficit(63)(62)(61)(60)(59)(59)(57)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:(14)(13)(12)(11)(10)(10)(9)
TOTAL LIABILITIES AND EQUITY:4444444

Income statement (P&L) ($ in millions)

12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
Revenues0000000
Revenue, net0000000
Cost of revenue
(Cost of Goods and Services Sold)
(0)(0)(0)(0)(0)(0)(0)
Other undisclosed gross profit      (0)
Gross profit:0000000
Operating expenses1(1)(1)(0)1(1)(0)
Other undisclosed operating income (loss)(2)00(0)(2)0(1)
Operating loss:(1)(0)(1)(1)(1)(1)(1)
Nonoperating expense (0)(0)  (0)(0)
Investment income, nonoperating 0(0)  (0)(0)
Interest and debt expense(0)(0)(0)(0)(1)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes1   1  
Loss from continuing operations before equity method investments, income taxes:(0)(1)(2)(1)(1)(1)(1)
Other undisclosed income (loss) from continuing operations before income taxes(1)00 (0)0 
Net loss available to common stockholders, diluted:(1)(1)(1)(1)(1)(1)(1)

Comprehensive Income ($ in millions)

12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
Net loss:(1)(1)(1)(1)(1)(1)(1)
Comprehensive loss, net of tax, attributable to parent:(1)(1)(1)(1)(1)(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: